Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC.
Filippo Gustavo Dall'OlioClaudia ParisiLaura MarcolinStefano BrocchiCaroline CaramellaNicole ConciGiulia CarpaniFrancesco GelsominoStefano ArdizzoniPaola Valeria MarcheseAlexandro PaccapeloGiada GrilliRita GolfieriBenjamin BesseAndrea ArdizzoniPublished in: Therapeutic advances in medical oncology (2022)
In the presence of PD, a decrease in TGR may result in a clinical benefit in patients treated with ICI but not with chemotherapy. Monitoring TGR changes after ICIs administration can help physician in deciding to treat beyond PD.